Development of canine immunotherapy targeted agents
Ended Awarded Last action
- Contract number
- 75N91021F00016
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,566,580
Award facts
- Contract value 100% obligated
- $6,566,580.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $109,311 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $6,457,269 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 16, 2021, with a ceiling value of $6.566 million for development of canine immunotherapy targeted agents under a cost-plus-fixed-fee pricing structure.
Place of performance is Frederick, MD. The order's ultimate completion date is September 15, 2026. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute and National Institutes of Health, delivering biomedical research and facilities support services across medical research, clinical trials, and advanced technological solutions.
Service Contract Inventory reporting shows actual government-invoiced labor climbing from $336 thousand in FY2021 to $1.4 million in FY2024. FY2024 reflects 4.7 FTEs across 9,725 contractor hours at a derived hourly rate of $144.29 per hour. The prime self-performed all reported hours; no subcontractors were reported on this order's SCI rows.
Quick answers
Who was awarded contract 75N91021F00016?
75N91021F00016 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2021.
How much is contract 75N91021F00016 worth?
The government has obligated $6,566,580 on 75N91021F00016.
Is contract 75N91021F00016 an order under another contract?
Yes. 75N91021F00016 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91021F00016 competed?
The extent of competition for 75N91021F00016 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award